The two index heavyweights Nestlé and Roche presented their quarterly figures last Wednesday; both traditional companies were convincing with their results.
Nestlé reported organic sales growth of 7.6%, beating not only analysts' expectations but also the results of rival Danone. Almost 70% of analysts recommend buying the stock, 30% expect market performance. ZKB Equity Research rates the stock as "overweight".
Roche's two divisions (Pharmaceuticals and Diagnostics) are also presenting strong quarters, which has enabled the group to revise its sales forecasts upwards. Roche also receives an "overweight" rating from ZKB Equity Research.
Accordingly, the market consensus forecasts an upward trend for these two stocks - In the case of barrier products, the probability of a barrier hit is thus assessed as lower while the coupon remains unchanged.
Callable BRC on Nestlé and Roche
Callable BRC on Nestlé and Roche
Capped Outperformance Certificate on Roche
*indicative
ZKB Callable Barrier Reverse Convertible on worst of Vale SA/Starbucks Corp/Adobe Inc 132912438 / CH1329124387 |
ZKB Callable Barrier Reverse Convertible on worst of SunPower Corp/Sunrun Inc 127344767 / CH1273447677 |
ZKB Autocallable Barrier Reverse Convertible auf ON Holding AG 127345566 / CH1273455662 |
ZKB Callable Barrier Reverse Convertible on worst of Swisscom AG/Kuehne + Nagel International AG/Sik... 130397238 / CH1303972389 |
ZKB Barrier Reverse Convertible on worst of ABB Ltd/Swisscom AG/Roche Holding AG/Swiss Re AG 127347485 / CH1273474853 |